Serial venous blood samples were obtained from 45 patients suffering myocardial infarction. Ten of these patients received 25 mg/kg methylprednisolone sodium succinate intravenously within 4 hours of the onset of chest pain. The activities of creatine kinase (CK) and its MB-isoenzyme were assayed in the plasma. A lysosomal enzyme, N-acetyl-,B-glucosaminidase (NAG) was also assayed. In the control group of patients the peak activity of CK occurred at a mean time of 21.3 ± 1.3 hours after the onset of chest pain, while the peak activities of CK-MB and NAG occurred at 18.1 ± 1.6 hours and 18.0 ± 1.0 hours, respectively. There was an exponential relationship between the peak values of CK and NAG activity and a linear relationship between peak CK-MB and NAG activity. In the patients who received methylprednisolone the peak enzyme activities were delayed until 27.1 hours for CK, 27.0 hours for CK-MB and 27.3 hours for NAG.
SUMMARY Serial venous blood samples were obtained from 45 patients suffering myocardial infarction. Ten of these patients received 25 mg/kg methylprednisolone sodium succinate intravenously within 4 hours of the onset of chest pain. The activities of creatine kinase (CK) and its MB-isoenzyme were assayed in the plasma. A lysosomal enzyme, N-acetyl-,B-glucosaminidase (NAG) was also assayed. In the control group of patients the peak activity of CK occurred at a mean time of 21.3 ± 1.3 hours after the onset of chest pain, while the peak activities of CK-MB and NAG occurred at 18.1 ± 1.6 hours and 18.0 ± 1.0 hours, respectively. There was an exponential relationship between the peak values of CK and NAG activity and a linear relationship between peak CK-MB and NAG activity. In the patients who received methylprednisolone the peak enzyme activities were delayed until 27.1 hours for CK, 27.0 hours for CK-MB and 27.3 hours for NAG.
The mean peak value for NAG activity was considerably lower in the treated patients, and there was no relationship between the activities of the lysosomal enzyme and either CK or CK-MB. These findings are consistent with previous experimental results which suggest that methylprednisolone can delay tissue damage and stabilize lysosomal membranes during acute myocardial ischemia.
METHYLPREDNISOLONE is an anti-inflammatory steroid which has been found to protect the heartl'4 and other tissues5 6 during experimental anoxia and ischemia. The mechanism by which this is achieved is thought to be stabilization of lysosomal and other subcellular membranes.7 8 Despite these encouraging experimental findings, clinical studies of this drug have failed to show any benefits to patients with acute myocardial infarction and some deleterious effects have been reported.9 However, in these previous investigations the drug was not administered until at least 12 hours after the onset of chest pain. When multiple doses were given they may have been continued for too long after myocardial necrosis was established.
The purpose of this study was to investigate the effects of a single dose of methylprednisolone, administered within 4 hours after the onset of chest pain in patients suffering uncomplicated acute myocardial infarction. The pattern and time course of changes in the plasma activities of both cytosolic and lysosomal enzymes were used to assess the effect of the drug.
Methods
We studied 45 patients (ages 45-77 years, mean 59 years) admitted to the coronary care unit at the Hammersmith Hospital. All had electrocardiographic evidence of acute myocardial infarction on the standard 12-lead ECG and all had a diagnostic rise in plasma enzyme activity.10 All patients were admitted within 6 hours after the onset of chest pain and during the 3-day period of study the following complications did not occur: 1) recurrent chest pain lasting more than 10 minutes; 2) clinical or X-ray evidence of congestive heart failure or pulmonary edema; 3) cardiac rhythm disturbances other than unifocal isolated ventricular ectopic beats; 4) multiple intramuscular injections; 5) any non-cardiac disease. Thirty-five of these patients received no therapeutic intervention after admission, other than diamorphine. Ten consecutive patients (six with anterior and four with inferior infarction) were given a single injection of 25 mg/kg methylprednisolone sodium succinate (Solu-Medrone, Upjohn Ltd) within 4 hours after the onset of chest pain. The drug was infused slowly over a period of 20-30 minutes.
Venous blood samples (5 ml) were obtained from each patient at 3-hour intervals during the first 30 hours after the onset of chest pain and then at 6-hour intervals for the next 2 days. The blood samples were placed in heparinized tubes and kept at 4°C. The plasma was separated as soon as possible by centrifugation at 2,500 g for 10 minutes and stored at 4°C for up to 3 days before assaying for enzyme activities. 
Results
Total CK Activity Total plasma CK activity showed a consistent pattern of changes in the control, untreated patients. An increase in activity was observed 6 hours after the onset of chest pain and continued to rise, giving maximum activity at 21.3 ± 1.3 hours (mean ± SD) ( fig.  1 ). In the patients treated with methylprednisolone, maximum plasma CK activity was not found until 27.1 ± 0.5 hours after the onset of chest pain. This delay in reaching peak CK activity was significant (p < 0.001), but the values of the peak activity were similar in both groups.
Enzyme Assays
Total plasma creatine kinase (CK) activity was measured at 25°C in a Cecil CE 272 spectrophotometer (Cecil Instruments, Cambridge, UK) using a modified reaction rate method." Samples with CK activity greater than 250 mU/ml were diluted with heatinactivated plasma to avoid the activation effects of other diluents.'2 The isoenzymes of CK were separated by electrophoresis on agarose gel and quantitated after elution by fluorimetry.13
Lysosomal N-acetyl-3-glucosaminidase (E.C. 3.2.1.30) was assayed fluorimetrically by a modification'4 of the method of Woollen and Walker.' The plasma was diluted with water to reduce the quenching effect of plasma constituents on the fluorescence of the product and protamine sulphate was added to the reaction mixture to prevent inhibition of the enzyme by heparin.
The changes in plasma enzyme activities were plotted against time after the onset of chest pain for each patient and from these the value and time for peak enzyme activity were obtained. These results were analyzed by linear regression analysis and by unpaired t tests.
CK-MB-Isoenzyme Activity
This cardiac-specific isoenzyme of CK reached maximum activity in plasma at 18.1 ± 1.6 hours in the control patients. This earlier time for peak activity may be due to a faster rate of plasma clearance of the MB-isoenzyme compared with the MM-isoenzyme ( fig. 2 ). In the patients treated with methylprednisolone, peak CK-MB activity was not observed until 27.0 ± 0.3 hours after the onset of chest pain (p < 0.001), but again the mean value of the maximum activity was similar to that of the control group.
N-acetyl-3-glucosaminidase (NAG) Activity
The pattern of changes in the plasma activity of this lysosomal enzyme was similar to that of CK-MB in the untreated patients ( fig. 3 ). Maximum activity was found at a mean time of 18.0 ± 1 hour after the onset of chest pain. In the treated patients there was a significant delay in reaching peak NAG activity, which occurred at 27.3 ± 0.3 hours (p < 0.001). In contrast to the cytosolic enzyme, the maximum values (mean ± SD) of NAG activity were lower in the treated patients than in untreated patients: 14.5 ± 0.5 mU/ml and 22.4 ± 0.9 mU/ml, respectively.
Relationship Between CK and NAG Activities
When the peak activities of CK and NAG were compared for each patient in the control group, an exponential relationship was observed ( fig. 4 ). When log CK was plotted against NAG, a linear relationship was found (r = 0.91) and the regression equation (CK) = 11.8 (NAG) -795 was used to plot the ex- NAG and CK-MB in the control group was linear (r= 0.98). The treated patients again showed a change in this relationship indicating relatively lower NAG levels compared with the control group ( fig. 5 ).
Discussion nential curve ( fig. 4) . The relationship between peak Methylprednisolone has been shown to preserve the activity and peak NAG activity in the treated mechanical viability of ischemic dog heart2 and anoxic tients is also shown in figure 4 , and it can be seen papillary muscle.' This effect is thought to be due to t in each case the lysosomal enzyme activity is stabilization of myocardial cell membranes. It has ver than that which could be expected from the CK been found that CK release from hypoxically perfused :ivity. rat heart or ischemic cat myocardium was reduced by the onset of symptoms. After cell death has occurred there is a healing phase during which the necrotic tissue is phagocytosed by leukocytes and macrophages, and scar tissue is formed.20 It may be dangerous to interfere with this mechanism and corticosteroids inhibit phagocytosis by inflammatory cells.2" For this reason it may be inadvisable to administer drugs such as methylprednisolone during the healing phase after acute myocardial infarction. This preliminary study on methylprednisolone in acute myocardial infarction has shown that a single dose of the drug, given within 4 hours after the onset of chest pain, can significantly alter the pattern of plasma enzyme changes. The times at which peak plasma CK and CK-MB activities occur are fairly constant among patients who suffer a single episode of chest pain, and the cardiac origin of the MBisoenzyme is well-established.'4 22 We have shown a close relationship between the changes in plasma CK-MB and N-acetyl-f-glucosaminidase activity in the first 48 hours after the onset of chest pain, and additional evidence of the cardiac origin of this rise in NAG activity has been reported."4 The delay in the time for peak enzyme activity seen in patients treated with methylprednisolone, while consistent with a delay in the breakdown of cellular membranes, is also consistent with the experimental findings that this drug can delay cellular damage.' The relative reduction of lysosomal enzyme release compared with cytosolic enzyme release suggests preferential stabilization of lysosomal membranes. The extent of cytosolic enzyme release did not appear to be reduced in the treated patients, but a larger group of patients needs to be studied to make comparisons of factors related to infarct size. Thus, we cannot conclude that the delay in cellular damage suggested by these findings resulted in a reduction of the final extent of necrosis, although there is ECG evidence that this may occur.23 Whether this drug, given in single or multiple doses in the early stages of the development of myocardial infarction, can reduce mortality or morbidity remains to be investigated.
